Live feed09:30:00·22dPRReleasevia QuantisnowDatroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor CandidatesByQuantisnow·Wall Street's wire, on your screen.AZN· AstraZeneca PLCHealth Care
